<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491296</url>
  </required_header>
  <id_info>
    <org_study_id>0034-07-EMC</org_study_id>
    <nct_id>NCT00491296</nct_id>
  </id_info>
  <brief_title>Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation
      combined with hyperthermia instillation is associated with elevated prostate specific antigen
      (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with
      a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA
      determination will obtain before each synergo therapy application and at cystoscopy with each
      patient also serving as a control.

      Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local
      hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or
      pt. with recurrent tu of bladder post TURT with BCGtreatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">June 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGO</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGO-intravesical chemotherapy instillation combined with hyperthermia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection

          -  PSA Prior synergo therapy application&lt;10

          -  Normal rectal examination

          -  Patients willing to sign informed consent according

        Exclusion Criteria:

          -  History of prostate cancer

          -  Previous history of TCC stage T2 or higher

          -  Invasive tu of bladder

          -  Prior pelvic radiotherapy or systemic chemotherapy

          -  Active prostatitis

          -  Active tuberculosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PEREZ DORON, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HAEMEK MEDICAL CENTER, UROLOGY DEPARTMENT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Perez Doron, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>haemek medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>doron perez, M.D.</last_name>
    <phone>+972-4-6495115</phone>
    <email>perez_do@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haemek MC</name>
      <address>
        <city>Afula</city>
        <zip>18100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of urology</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>doron perez, M.D.</last_name>
      <phone>+972-4-6495115</phone>
      <email>perez_do@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>November 5, 2008</last_update_submitted>
  <last_update_submitted_qc>November 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2008</last_update_posted>
  <keyword>S/P Transuretral resection of bladder tumor</keyword>
  <keyword>Recurrent tumor after BCG Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

